Характерні риси специфічної ферментативної функції тромбіна та їх зв\'язок із структурою

Серейська, А. О.

doi:10.7124/bc.00040D

Biopolym. Cell. 1996; 12(1):5-15.

http://dx.doi.org/10.7124/bc.00040D

Характерні риси специфічної ферментативної функції тромбіна та їх зв'язок із структурою

1Серейська А. О.

Інститут біоорганічної хімії та нафтохімії НАН України
вул. Мурманська, 1, Київ, Україна, 02094

Abstract

В огляді наведено відомості щодо особливостей структури тромбіна, які впливають на високу селективність та ефективність його дії у системі згортання кровію Розглядається значення додаткового екзосайту впізнавання – зв'язування ферменту у взаємодії з фібриногеном. Обговорюється можливість виникнення конформаційних змін внаслідок утворення комплексу фібриноген – тромбін, що спричинює прискорення каталітичного процесу.

Повний текст: (PDF, російською)

References

[1] Hartley BS. The active centers of serine proteinases. Ann N Y Acad Sci. 1974;227:438-45.

[2] Izquierdo C, Burguillo FJ. Synthetic substrates for thrombin. Int J Biochem. 1989;21(6):579-92.

[3] Serebryanyy SB. Thrombin, its structure and features of catalysis.. Biokhimiya i fiziologiya zhivotnykh i cheloveka. 1982;6: 14-26.

[4] Sereyskaya AA, Karabut LV, Shchechkin IE. On the efficiency and selectivity of thrombin catalysis. Thromb Res. 1994;74(5):549-50.

[5] Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989;8(11):3467-75.

[6] Stubbs MT, Oschkinat H, Mayr I, Huber R, Angliker H, Stone SR, Bode W. The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem. 1992;206(1):187-95.

[7] Martin PD, Robertson W, Turk D, Huber R, Bode W, Edwards BF. The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. J Biol Chem. 1992;267(11):7911-20.

[8] Sereiskaya AA, Karabut LV, Smirnova IV, Shchechkin IE. Interaction of additional center of thrombin with a complementary site of fibrinogene. Doklady Akad Nauk Ukr SSR. 1991; (11):140-3.

[9] Karabut LV, Sereyskaya AA. The peculiarities of thrombin binding sites structure. Putative mechanisms of interaction with highmolecular and small substrates. Biopolym Cell. 1992; 8(5):31-5.

[10] Karabut LV, Shchechkin IE, Serejskaya AA. Modelling of thrombin-fibrinogen recognition complex. Biopolym Cell. 1994; 10(6):83-7.

[11] Tsukada H, Blow DM. Structure of alpha-chymotrypsin refined at 1.68 A resolution. J Mol Biol. 1985;184(4):703-11.

[12] Kibirev VK, Sereyskaya AA. Structural bases of thrombin specificity. Biokhimiya zhivotnykh i cheloveka.. 1989; 13: 10-18.

[13] Chang JY. Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate. Eur J Biochem. 1985;151(2):217-24.

[14] Banner DW, Hadv?ry P. Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem. 1991;266(30):20085-93.

[15] Bode W, Turk D, St?rzebecher J. Geometry of binding of the benzamidine- and arginine-based inhibitors N alpha-(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-pipe ridine (NAPAP) and (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulphonyl)-L-arginyl]-2-piperidine carboxylic acid (MQPA) to human alpha-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur J Biochem. 1990;193(1):175-82.

[16] Poiarkova SA, Kibirev VK, Serebriany? SB. Inhibitory effect of methyl esters of arginine-containing oligopeptides on thrombin and trypsin. Ukr Biokhim Zh. 1987;59(5):5-11.

[17] Poiarkova SA, Kibirev NK, Serebriany? SB. Inhibition of the proteolytic activity of thrombin by methyl esters of arginine-containing oligopeptides. Ukr Biokhim Zh. 1986;58(6):3-8.

[18] Magnusson S, Petersen TE. Proteases a. biological control. Conf. on cell proliferation: Abstr. New York: Cold Spring Harbor Lab., 1975;2: 123-49.

[19] Sereyskaya AA. On thrombin supespecificity. Molekulyarnaya biologiya (Kiev). 1980; 27: 68-79.

[20] Fenton JW 2nd. Thrombin specificity. Ann N Y Acad Sci. 1981;370:468-95.

[21] Karshikov A, Bode W. Electrostatic properties of thrombin: importance for structural stabilization and ligand binding. Semin Thromb Hemost. 1993;19(4):334-43.

[22] Fenton JW 2nd, Olson TA, Zabinski MP, Wilner GD. Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition. Biochemistry. 1988;27(18):7106-12.

[23] Whinna HC, Church FC. Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor. J Protein Chem. 1993;12(6):677-88.

[24] Seegers WH, Hassouna H, Walz G. et al. Prothrombin and thrombin. Selected aspects of thrombin formation, properties, inhibition and immunology. Sem Thromb Hemost. 1975; 1(3):211-83.

[25] Hofsteenge J, Braun PJ, Stone SR. Enzymatic properties of proteolytic derivatives of human alpha-thrombin. Biochemistry. 1988;27(6):2144-51.

[26] Henriksen RA, Mann KG. Identification of the primary structural defect in the dysthrombin thrombin Quick I: substitution of cysteine for arginine-382. Biochemistry. 1988;27(26):9160-5.

[27] Hogg DH, Blomb?ck B. The mechanism of the fibrinogen-thrombin reaction. Thromb Res. 1978;12(6):953-64.

[28] Scheraga HA. Chemical basis of thrombin interactions with fibrinogen. Ann N Y Acad Sci. 1986;485:124-33.

[29] Sere?skaia AA, Smirnova IV, Karabut LV, Chetyrkina SN. The critical role of the interaction of anion-binding thrombin exosite with complementary segment of the Aalpha-chain of fibrinogen in detecting high specificity of the enzyme. Biokhimiia. 1994;59(3):360-7.

[30] Binnie CG, Lord ST. A synthetic analog of fibrinogen alpha 27-50 is an inhibitor of thrombin. Thromb Haemost. 1991;65(2):165-8.

[31] Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW 2nd. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990;29(30):7095-101.

[32] Hopfner KP, Ayala Y, Szewczuk Z, Konishi Y, Di Cera E. Chemical compensation in macromolecular bridge-binding to thrombin. Biochemistry. 1993;32(12):2947-53.

[33] Rydel TJ, Tulinsky A, Bode W, Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol. 1991;221(2):583-601.

[34] Parry MA, Stone SR, Hofsteenge J, Jackman MP. Evidence for common structural changes in thrombin induced by active-site or exosite binding. Biochem J. 1993;290 ( Pt 3):665-70.

[35] Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JW 2nd. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry. 1994;33(11):3266-79.

[36] Church FC, Lundblad RL, Noyes CM. Modification of histidines in human prothrombin. Effect on the interaction of fibrinogen with thrombin from diethyl pyrocarbonate-modified prothrombin. J Biol Chem. 1985;260(8):4936-40.

[37] Lundblad RL, Noyes CM, Featherstone GL, Harrison JH, Jenzano JW. The reaction of bovine alpha-thrombin with tetranitromethane. Characterization of the modified protein. J Biol Chem. 1988;263(8):3729-34.

[38] Le Bonniec BF, Guinto ER, MacGillivray RT, Stone SR, Esmon CT. The role of thrombin's Tyr-Pro-Pro-Trp motif in the interaction with fibrinogen, thrombomodulin, protein C, antithrombin III, and the Kunitz inhibitors. J Biol Chem. 1993;268(25):19055-61.

[39] Dufton MJ. Could domain movements be involved in the mechanism of trypsin-like serine proteases? FEBS Lett. 1990;271(1-2):9-13.